OvaScience Inc. (NASDAQ:OVAS)’s share price shot up 3.1% during trading on Monday . The stock traded as high as $5.80 and last traded at $5.72, with a volume of 59,117 shares changing hands. The stock had previously closed at $5.55.

Several research firms have commented on OVAS. JMP Securities reaffirmed a “neutral” rating on shares of OvaScience in a report on Wednesday, August 10th. Zacks Investment Research raised OvaScience from a “hold” rating to a “buy” rating and set a $7.00 price target for the company in a report on Wednesday, August 10th. JPMorgan Chase & Co. cut their price target on OvaScience from $9.00 to $8.00 and set a “neutral” rating for the company in a report on Friday, August 5th. Credit Suisse Group AG reaffirmed a “sell” rating on shares of OvaScience in a report on Tuesday, July 12th. Finally, Leerink Swann reaffirmed a “hold” rating and issued a $7.00 price target (up previously from $6.00) on shares of OvaScience in a report on Sunday, May 8th. One research analyst has rated the stock with a sell rating, four have given a hold rating and three have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $10.98.

The firm’s market cap is $214.79 million. The company has a 50 day moving average of $5.66 and a 200 day moving average of $7.11.

OvaScience (NASDAQ:OVAS) last announced its quarterly earnings data on Thursday, August 4th. The company reported ($0.62) EPS for the quarter, beating the consensus estimate of ($0.78) by $0.16. The firm had revenue of $0.19 million for the quarter, compared to analyst estimates of $0.21 million. The firm’s revenue for the quarter was up 530.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.64) earnings per share. On average, analysts expect that OvaScience Inc. will post ($2.66) earnings per share for the current fiscal year.

OvaScience, Inc is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.